DaVita vs Halozyme Therapeutics

DaVita (DVA), health care, and Halozyme Therapeutics (HALO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

DaVita and Halozyme Therapeutics are valued at about the same: $10.9B and $10.9B. DaVita trades at 13.1 times earnings and Halozyme Therapeutics at 24.0; operating margins in their latest fiscal years were 15.0% and 33.6%. Over the past year DaVita's share price has moved +49.5% and Halozyme Therapeutics's +37.7%.

Key facts

DaVita market value
$10.9B
Halozyme Therapeutics market value
$10.9B
DaVita P/E
13.1
Halozyme Therapeutics P/E
24.0
DaVita revenue
$13.6BFY to 2025-12-31
Halozyme Therapeutics revenue
$1.4BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

DaVita vs Halozyme Therapeutics: every measure side by side
Measure DaVita Halozyme Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.9Blower$10.9Bhigher
Revenue$13.6Bhigher$1.4Blower
Earnings$746.8Mhigher$316.9Mlower
Employees78,000higher423lower
Total assets$17.5Bhigher$2.5Blower
Valuation
P/E13.1lower24.0higher
P/S0.8lower7.8higher
P/B——
Dividend yield0.00%0.00%
Profitability
Operating margin15.0%lower33.6%higher
Balance sheet
Net assets-$651.1Mlower$48.8Mhigher
Total liabilities$16.3Bhigher$2.5Blower
Total debt$10.3Bhigher$2.1Blower
Cash on hand$676.4Mhigher$133.8Mlower
Price change
Today-0.70%lower-0.55%higher
1 year+49.5%higher+37.7%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

DaVita only (1)

Percentages are each holding's share of that investor's reported portfolio (under "Both": DaVita / Halozyme Therapeutics). Who owns DVA · Who owns HALO

Further comparisons

Learn

Questions and answers

Which is bigger, DaVita or Halozyme Therapeutics?

By market value, Halozyme Therapeutics is the larger: $10.9B against $10.9B for DaVita. By revenue in its latest fiscal year, DaVita is the larger: $13.6B against $1.4B for Halozyme Therapeutics.

Which has the higher P/E ratio?

Halozyme Therapeutics: 24.0, against 13.1 for DaVita. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Halozyme Therapeutics: 33.6%, against 15.0% for DaVita. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

DaVita: $10.3B, against $2.1B for Halozyme Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both DaVita and Halozyme Therapeutics?

In their latest 13F filings, Josef Lakonishok holds both.

Cite this page

Funkfolio, “DaVita vs Halozyme Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/dva-vs-halo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.